Abstract
Background: Although FOLFOX4 is considered the standard chemotherapy regimen for colorectal cancer (CRC), few data are available on its results in human immunodeficiency (HIV)-related CRC. The results were analyzed to evaluate feasibility and activity of FOLFOX4 plus highly active antiretroviral therapy (HAART) in metastatic CRC (mCRC) HIV-seropositive patients. Patients and Methods: From January 2002 to March 2007, 24 patients were selected among the CRC HIV-seropositive patients treated with FOLFOX4 and concomitant HAART within the Italian Cooperative Group on AIDS and Tumors (GICAT). Results: Four median cycles of chemotherapy were administered; the most common severe toxicity was neutropenia (37.5%). An overall response rate of 50% was observed; 4.2% of patients achieved complete response and 45.8% partial response. No opportunistic infections occurred during or immediately after chemotherapy. The medi+ count was 380 (range 220-570) at diagnosis. Conclusions: To our knowledge, this is the largest study describing activity and tolerability of FOLFOX4 and HAART, in this setting. FOLFOX4 plus concomitant HAART resulted feasible and active also in HIV-seropositive patients. Moreover, the concomitant use of HAART did not seem to increase the FOLFOX4 toxicity. This study suggests the good tolerability of the FOLFOX4, making it a reasonable option for combination with HAART.
Keywords: Metastatic Colorectal Cancer, FOLFOX4, HIV-infection, HAART, chemotherapy, treatment
Current HIV Research
Title: Oxaliplatin Based Chemotherapy and Concomitant Highly Active Antiretroviral Therapy in the Treatment of 24 Patients with Colorectal Cancer and HIV Infection
Volume: 8 Issue: 3
Author(s): Massimiliano Lanzafame, Umberto Tirelli, Lorenza Guella, Annalisa Ridolfo, Elisa Garlassi, Clara Schiantarelli, Rossella Fisichella, Salvatore Berretta, Francesco Basile, Guglielmo Nasti, Massimiliano Berretta, Immacolata Izzi, Vincenzo Montesarchio, Giuseppe Nunnari, Bruno Cacopardo, Renato Talamini, Michele Spina, Alessandra Bearz, Alessandro Cappellani and Arben Lleshi
Affiliation:
Keywords: Metastatic Colorectal Cancer, FOLFOX4, HIV-infection, HAART, chemotherapy, treatment
Abstract: Background: Although FOLFOX4 is considered the standard chemotherapy regimen for colorectal cancer (CRC), few data are available on its results in human immunodeficiency (HIV)-related CRC. The results were analyzed to evaluate feasibility and activity of FOLFOX4 plus highly active antiretroviral therapy (HAART) in metastatic CRC (mCRC) HIV-seropositive patients. Patients and Methods: From January 2002 to March 2007, 24 patients were selected among the CRC HIV-seropositive patients treated with FOLFOX4 and concomitant HAART within the Italian Cooperative Group on AIDS and Tumors (GICAT). Results: Four median cycles of chemotherapy were administered; the most common severe toxicity was neutropenia (37.5%). An overall response rate of 50% was observed; 4.2% of patients achieved complete response and 45.8% partial response. No opportunistic infections occurred during or immediately after chemotherapy. The medi+ count was 380 (range 220-570) at diagnosis. Conclusions: To our knowledge, this is the largest study describing activity and tolerability of FOLFOX4 and HAART, in this setting. FOLFOX4 plus concomitant HAART resulted feasible and active also in HIV-seropositive patients. Moreover, the concomitant use of HAART did not seem to increase the FOLFOX4 toxicity. This study suggests the good tolerability of the FOLFOX4, making it a reasonable option for combination with HAART.
Export Options
About this article
Cite this article as:
Lanzafame Massimiliano, Tirelli Umberto, Guella Lorenza, Ridolfo Annalisa, Garlassi Elisa, Schiantarelli Clara, Fisichella Rossella, Berretta Salvatore, Basile Francesco, Nasti Guglielmo, Berretta Massimiliano, Izzi Immacolata, Montesarchio Vincenzo, Nunnari Giuseppe, Cacopardo Bruno, Talamini Renato, Spina Michele, Bearz Alessandra, Cappellani Alessandro and Lleshi Arben, Oxaliplatin Based Chemotherapy and Concomitant Highly Active Antiretroviral Therapy in the Treatment of 24 Patients with Colorectal Cancer and HIV Infection, Current HIV Research 2010; 8 (3) . https://dx.doi.org/10.2174/157016210791111061
DOI https://dx.doi.org/10.2174/157016210791111061 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Cancer with Epi-Drugs: A Precision Medicine Perspective
Current Pharmaceutical Biotechnology Chemotherapy with si-RNA and Anti-Cancer Drugs
Current Drug Delivery Exosomes Harnessed as Nanocarriers for Cancer Therapy - Current Status and Potential for Future Clinical Applications
Current Molecular Medicine Nanoemulsion: A Novel Eon in Cancer Chemotherapy
Mini-Reviews in Medicinal Chemistry Investigating the Association Between miR-608 rs4919510 and miR-149 rs2292832 with Colorectal Cancer in Iranian Population
MicroRNA New Advances in the Pathogenesis and Progression of Barrett’s Esophagus
Current Molecular Medicine Protein-Protein Interactions and Cancer: Targeting the Central Dogma
Current Topics in Medicinal Chemistry Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer
Combinatorial Chemistry & High Throughput Screening Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers
Current Pharmaceutical Design Synthesis, Cytotoxicity and Antioxidant Activity of New Analogs of RC-121 Synthetic Derivatives of Somatostatin
Anti-Cancer Agents in Medicinal Chemistry Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Novel Anticancer Agents and Targets: Recent Advances and Future Perspectives
Mini-Reviews in Medicinal Chemistry Application of Serial Analysis of Gene Expression in Cancer Research
Current Pharmaceutical Biotechnology Guide for Selection of Relevant Cell Lines During the Evaluation of new Anti-Cancer Compounds
Anti-Cancer Agents in Medicinal Chemistry EDITORIAL (Thematic Issue: Special Thematic Issuue: Development of Biomarkers in Tumors of Digestive System Part I)
Anti-Cancer Agents in Medicinal Chemistry Withdrawal Notice: Electrophoresis as a Tool for Early Cancer Diagnosis
Anti-Cancer Agents in Medicinal Chemistry Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design Comparative Evaluation of Colon Cancer Specific Antigen-2 Test and Chromocolonoscopy for Early Detection of Egyptian Patients with Colorectal Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Bioinformatic Approaches in Glycomics and Glycoproteomics
Current Proteomics